The Vascular Solutions acquisition was financed utilizing borrowings under the amended and restated credit agreement, dated January 20, 2017 (the "Credit Agreement"), which is described in Note 8.

The following table presents the purchase price allocation among the assets acquired and liabilities assumed with respect to the Vascular Solutions acquisition:

<table><tr><td></td><td>(Dollars in thousands)</td></tr><tr><td>Assets</td><td></td></tr><tr><td>Current assets</td><td>$                   61,592</td></tr><tr><td>Property, plant and equipment</td><td>45,533</td></tr><tr><td>Intangible assets</td><td>539,250</td></tr><tr><td>Goodwill</td><td>524,872</td></tr><tr><td>Other assets</td><td>728</td></tr><tr><td>Total assets acquired</td><td>1,171,975</td></tr><tr><td>Less:</td><td></td></tr><tr><td>Current liabilities</td><td>15,079</td></tr><tr><td>Deferred tax liabilities</td><td>181,372</td></tr><tr><td>Liabilities assumed</td><td>196,451</td></tr><tr><td>Net assets acquired</td><td>$                  975,524</td></tr></table>

The goodwill resulting from the Vascular Solutions acquisition primarily reflects synergies currently expected to be realized from the integration of the acquired business and is not fully tax deductible.

The following table sets forth the components of identifiable intangible assets acquired and the ranges of the useful lives as of the date of the Vascular Solutions acquisition:

<table><tr><td></td><td>Fair value</td><td>Useful life range</td></tr><tr><td></td><td>(Dollars in thousands)</td><td>(Years)</td></tr><tr><td>Intellectual property</td><td>$            248,200</td><td>10­ 20</td></tr><tr><td>In­process research and development ("IPR&D")</td><td>15,600</td><td>Indefinite</td></tr><tr><td>Trade names</td><td>16,650</td><td>20</td></tr><tr><td>Customer relationships</td><td>258,800</td><td>25</td></tr></table>

# NeoTract, Inc.

On October 2, 2017, the Company acquired NeoTract, Inc. ("NeoTract"), a medical device company that developed and commercialized the UroLift System, a minimally invasive medical device for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. The fair value of consideration transferred by the Company was \$975.2 million, which included initial payments of \$725.6 million in cash less a favorable working capital adjustment of \$1.4 million (for which the Company had not yet received payment as of December 31, 2017) and \$251.0 million in estimated fair value of contingent consideration. The contingent consideration liability represents the estimated fair value of the Company's obligations, under the acquisition agreement, to make four milestone payments of up to \$375 million in the aggregate if certain sales goals are met. The milestone payments are based on net sales (as defined in the acquisition agreement) for the periods from January 1, 2018 through April 30, 2018 and the years ended December 31, 2018, 2019 and 2020. The fair value of the contingent consideration was estimated using a Monte Carlo valuation approach. See Note 10 for additional information on the fair value measurement of the contingent consideration. The acquisition was financed using borrowings under the Company's revolving credit facility.

For the year ended December 31, 2017, the Company incurred \$10.1 million in transaction expenses associated with the NeoTract acquisition, which are included in selling, general and administrative expenses in the consolidated statement of income. For the year ended December 31, 2017, the Company recorded post acquisition revenue and operating loss of\$39.0 million and \$13.3 million, respectively, related to NeoTract. Financial information of NeoTract is primarily presented within the newly established Interventional Urology North America operating segment, which is included in the "all other" category in the Company's presentation of segment information.

The following table presents the purchase price allocation among the assets acquired and liabilities assumed with respect to the NeoTract acquisition:

<table><tr><td></td><td>(Dollars in thousands)</td></tr><tr><td>Assets</td><td></td></tr><tr><td>Current assets</td><td>$                   32,887</td></tr><tr><td>Property, plant and equipment</td><td>6,980</td></tr><tr><td>Intangible assets</td><td>763,314</td></tr><tr><td>Goodwill</td><td>341,171</td></tr><tr><td>Other assets</td><td>184</td></tr><tr><td>Total assets acquired</td><td>1,144,536</td></tr><tr><td>Less:</td><td></td></tr><tr><td>Current liabilities</td><td>13,580</td></tr><tr><td>Deferred tax liabilities</td><td>155,806</td></tr><tr><td>Liabilities assumed</td><td>169,386</td></tr><tr><td>Net assets acquired</td><td>$                  975,150</td></tr></table>

The Company is continuing to evaluate the initial purchase price allocations in connection with its acquisition of NeoTract, and further adjustments may be necessary as a result of the Company's assessment of additional information related to the fair values of the assets acquired and liabilities assumed, primarily deferred tax liabilities, certain intangible assets and goodwill. The goodwill resulting from the NeoTract acquisition primarily reflects the benefit the Company expects to realize from the establishment of new customer relationships and the development of technology resulting from the operation of NeoTract's business. Goodwill arising from the NeoTract acquisition is not tax deductible.

The following table sets forth the components of identifiable intangible assets acquired and the ranges of the useful lives as of the date of the NeoTract acquisition:

<table><tr><td rowspan="2"></td><td>Fair value</td><td>Useful life</td></tr><tr><td>(Dollars in thousands)</td><td>(Years)</td></tr><tr><td>Intellectual property</td><td>$             492,118</td><td>15</td></tr><tr><td>Trade names</td><td>161,637</td><td>25</td></tr><tr><td>Customer relationships</td><td>109,559</td><td>15</td></tr></table>

# Tianjin Medis Medical Device Co. LTD

On September 15, 2017, the Company acquired certain assets from one of its contract manufacturers, Tianjin Medis Medical Co. LTD ("Tianjin Medis"), consisting of substantially all of the assets used by Tianjin Medis to manufacture a line of the Company's laryngeal masks. The aggregate consideration transferred for the assets was \$21.3 million, which included payments of \$16.0 million and \$5.3 million in estimated fair value of contingent consideration. The assets acquired include goodwill and finite­lived intangible assets (consisting of intellectual property, customer relationships and a non­compete agreement) of \$14.7 million and \$6.9 million, respectively. The goodwill resulting from the acquisition primarily reflects synergies currently expected to be realized from the integration of the acquired business and is not tax deductible.

# Pyng Medical Corp

On April 3, 2017, the Company completed the acquisition of Pyng Medical Corp ("Pyng"), a medical device company that developed and marketed sternal intraosseous infusion products, which complement the Company's anesthesia product portfolio. The Company acquired all of the issued and outstanding common shares of Pyng utilizing available cash. The aggregate consideration was \$17.9 million, net of cash acquired. The assets acquired include goodwill and finite­lived intangible assets (primarily intellectual property and customer relationships) of \$13.0 million and \$5.5 million, respectively. The goodwill resulting from the acquisition primarily reflects synergies currently expected to be realized from the integration of the acquired business and is not tax deductible.